TY - JOUR T1 - Functional Assessment <em>In Vivo</em> of the Mouse Homolog of the Human Ala-9-Ser NHE6 Variant JF - eneuro JO - eNeuro DO - 10.1523/ENEURO.0046-19.2019 VL - 6 IS - 6 SP - ENEURO.0046-19.2019 AU - Qing Ouyang AU - Lena Joesch-Cohen AU - Sasmita Mishra AU - Hasib A. Riaz AU - Michael Schmidt AU - Eric M. Morrow Y1 - 2019/11/01 UR - http://www.eneuro.org/content/6/6/ENEURO.0046-19.2019.abstract N2 - Christianson syndrome (CS) is an X-linked neurogenetic disorder resulting from loss-of-function (LoF) mutations in SLC9A6, which encodes the endosomal Na+/H+ exchanger 6 (NHE6). NHE6 regulates proton efflux from endosomes and, thus, participates in regulating cargo processing and trafficking. LoF mutations in NHE6 cause aberrant acidification of endosomes. While CS arises in males generally due to clear LoF mutations, other potentially hypomorphic variants have emerged, yet most of these variants have not been evaluated for functional effects, particularly in vivo. Here we characterize an SLC9A6 variant that has been previously reported in patients, yet now also appears in exome datasets of largely control individuals—c.25G&gt;T, p.A9S. By heterologous expression in cell lines, we show that human NHE6A9S is expressed and localizes in a manner comparable to control NHE6. By genome editing, we generated the equivalent NHE6 mutation in mouse—p.A11S—and determined that male NHE6A11S mice have normal brain size at 6 months of age and do not show cerebellar degeneration or defective neuronal arborization. Neurons from male NHE6A11S mice also did not demonstrate an abnormality in intraendosomal pH compared with controls. These findings are in contrast to findings in NHE6-null mice previously reported and indicate that the NHE6A11S variant functions at a level equivalent to control NHE6 for many of the assays performed. These data stand in support of the population genetic data, which are also evaluated here, indicating that the A9S variant is unlikely to confer disease susceptibility with high penetrance. ER -